ASH 2023 | Validation of IWG 2023 criteria for response to treatment with HMA in HR-MDS
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on a study validating the newly proposed International Working Group (IWG) 2023 criteria defining response to treatment in patients with higher-risk myelodysplastic syndromes (HR-MDS) who are treated with hypomethylating agents (HMA). A retrospective analysis validated the use of composite complete response (cCR) as an endpoint, with these patients having an improved overall survival (OS) compared to patients who did not achieve cCR. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
